|
No. 5 March 15, 2010
159. Randomized Phase III Trial of Vinorelbine plus Cisplatin Compared with Observation in Completely Resected Stage Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10.
Charles A. Butts, et al. Journal of Clinical Oncology 2010 28(1):29
160. Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer.
Rodrigo Arriagada, et al. Journal of Clinical Oncology 2010 28(1):35
161. Tracheoesophageal Fistula Formation in Patients with Lung Cancer Treated with Chemoradiation and Bevacizumab.
David R. Spigel, et al. Journal of Clinical Oncology 2010 28(1):43
162. Randomized, Double-Blind Trial of Carboplatin and Paclitaxel with Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study.
Glenwood D. Goss, et al. Journal of Clinical Oncology 2010 28(1):49
163. Carboplatin and Paclitaxel in Combination with Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer.
Suresh S. Ramalingam, et al. Journal of Clinical Oncology 2010 28(1):56
164. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients with Non-Small-Cell Lung Cancer.
Emer O.Hanrahan, et al. Journal of Clinical Oncology 2010 28(2):193
165. Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Patients with Pulmonary Dysfunction: CAlGB 39904.
Jeffrey A. Bogart, et al. Journal of Clinical Oncology 2010 28(2):202
166. Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers.
Allison W. Kurian, et al. Journal of Clinical Oncology 2010 28(2):222
167. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer.
David Jackman, et al. Journal of Clinical Oncology 2010 28(2):357
168. Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients with Non-Small-Cell Lung Cancer.
Young Joo Lee, et al. Journal of Clinical Oncology 2010 28(3):487
169. Stage III vs. stage IV lung cancer: “crossing a Great Divide”.
L.B.Marks, et al. Lung Cancer 2010 67(1):1
170. Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates.
C.Langer, et al. Lung Cancer 2010 67(1):4
171.Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells.
H. Kuroda, et al. Lung Cancer 2010 67(1):31
172.14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion.
A.Xu, et al. Lung Cancer 2010 67(1):48
173. Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
O.D.Roe, et al. Lung Cancer 2010 67(1):57
174.Molecular analysis of the HuD gene in neuroendocrine lung cancers.
V.D’Alessandro, et al. Lung Cancer 2010 67(1):69
175.18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis.
I.I.Na, et al. Lung Cancer 2010 67(1):76
176. Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer.
P. Bonfili, et al. Lung Cancer 2010 67(1):81
177. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
C.Gridelli, et al. Lung Cancer 2010 67(1):86
178. Lung pathology in Fatal Human Influenza A (H1N1) Infection.
Thais Mauad, et al. Am J Respir Crit Care Med 2010 181(1):72
179 .HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality.
Neel R. Gandhi, et al. Am J Respir Crit Care Med 2010 181(1):80
180. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects.
John Z.Metcalfe, et al. Am J Respir Crit Care Med 2010 181(1):87
181.Neutrophils Are the Predominant Infected Phagocytic Cells in the Airways of Patients with Active Pulmonary TB.
Seok-Yong Eum，et al. Chest 2010 137(1):122
182. Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of Adults: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study.
John L. Hankinson, et al. Chest 2010 137(1):146
183. Do diagnostic delays in cancer matter?
RD Neal, British Journal of Cancer 2010 101(2):9
184. Development of a measurement tool to assess public awareness of cancer.
S Stubbings，et al. British Journal of Cancer 2010 101(2):13
185. Cd133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Alexei V. Salnikov, International Journal of Cancer 2010 126(4):950
186. Treatment of Older patients with Non—Small-Cell Lung Cancer: Walking the Therapeutic Tightrope.
George R.Simon Journal of Clinical Oncology 2010 28(4):523
187. Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients with Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study NO426.
Alex A.Adjei, et al. Journal of Clinical Oncology 2010 28(4):614
188. Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.
Elizabeth A.Chrischilles, et al. Journal of Clinical Oncology 2010 28(4):620
189. Sources of Bias in Specimens for Research about Molecular Markers for Cancer.
David F.Ransohoff, et al. Journal of Clinical Oncology 2010 28(4):698
190. Global lung health:the colliding epiding epidemics of tuberculosis, tobacco smoking, HIV and COPD.
R.N.van Zyl Smit, et al. European Respiratory Journal 2010 35(1):27
191. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes.
E. Calabro, et al. European Respiratory Journal 2010 35(1):146
192. Genetic association Study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer.
C.M.Wright, et al. European Respiratory Journal 2010 35(1):152
193. Conundrums in screening for cancer.
Anthony B.Miller, et al. International Journal of Cancer 2010 126(5):1039
194. Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetycysteine.
Roumen Balansky, et al. International Journal of Cancer 2010 126(5):1047
195. Timp-2 binding with cellular MT1-MMp stimulates invasion-promoting MEK/ERK signaling in cancer cells.
Nor Eddine Sounni，et al. International Journal of Cancer 2010 126(5):1067
196.Stage I Nonsmall Cell Lung Cancer in Patients Aged≥75 Years: Outcomes after Stereotactic Radiotherapy
Cornelis J.A.Haasbeek, et al. Cancer 2010 116(2):406
197. Health Status of the Oldest Adult Survivors of Cancer During Childhood.
Lisa B Kenney, et al. Cancer 2010 116(2):497
198. CancerScope: Oncology Issues in Focus
Carrie Printz Cancer 2010 116(3):541
199. Prognostic Significance of Grading in Lung Adenocarcinoma
Justine A.Barletta,et al. Cancer 2010 116(3):659
200. Pack-Years of Cigarette Smoking as a Prognostic Factor in Patients with Stage IIIB/IV Nonsmall Cell Lung Cancer.
Yelena Y. Janjigian, et al. Cancer 2010 116(3):670
201. Cancer and the Environment: the American Cancer Society Prevention Priorities.
Graham A.Colditz,et al. CA Cancer J Clin. 2009 59(6):341
202. American Cancer Society Perspectives on Environmental Factors and Cancer.
Elizabeth T.H.Fontham, et al. CA Cancer J Clin. 2009 59(6):343
203. Adult Cancer Survivorship: Evolution, Research, and Planning Care.
Linda A.Jacobs, et al. CA Cancer J Clin. 2009 59(6):391
204. Reduction of Tumstatin in Asthmatic Airways Contributes to Angiogenesis, Inflammation, and Hyperresponsiveness.
Janette K. Burgess,et al. Am J Respir Crit Care Med. 2010 181(2):106
|
